In conclusion, we have identified that the combination of trametinib and dexamethasone is synergistic in RAS-mutant myeloma cells, particularly in those with elevated NDRG1 expression and is associated with suppression of PDK1 signalling. This evidence concerns the gene PDK1 and plasma cell myeloma.